Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC410 Plus Pembrolizumab in Advanced Solid Tumors
NCT05572684Phase 2Terminated
- Sponsor
- NextCure, Inc.
- Start
- Oct 2022
- Primary completion
- Apr 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NC410 in solid tumor, sponsored by NextCure, Inc. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events. Started Oct 2022; status: terminated.
02
Drugs
NC410
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05572684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05572684.